News
Disease progression and therapy response vary in MS by ethnicity
- Author:
- Randy Dotinga
African Americans and Hispanics had more severe illness than Caucasians, and there were other differences as well.
News
Newly approved drugs offer new hope in NMOSD
- Author:
- Randy Dotinga
Trio of medications offer relief from relapses, neurologist tells colleagues
News
Infections – especially urinary and kidney – are higher in MS
- Author:
- Randy Dotinga
Among patients with MS, the infection rate was more than quadruple the rate in a control cohort.
News
Anti-CD20s linked to higher COVID-19 severity in MS
- Author:
- Randy Dotinga
Older age and disability are also linked to extra risk, registries find, but not other DMTs.
News
Certain DMTs in MS may attenuate COVID-19 vaccines
- Author:
- Randy Dotinga
Adjust timing if feasible, neurologist says, but focus on getting shots in arms.
News
COVID-19: Another study links colchicine to better results
- Author:
- Randy Dotinga
Brazilian trial tested gout drug against placebo in hospitalized patients.
News
Meta-analysis: No evidence that SNRIs relieve back pain
- Author:
- Randy Dotinga
But antidepressants may provide relief for knee OA and sciatica.
News
Vitiligo treatment options abound but consider patient goals
- Author:
- Randy Dotinga
Before turning to therapy, he said, make sure to understand what the patient wants.
News
Preadolescent acne: Management from birth requires increasing vigilance
- Author:
- Randy Dotinga
No treatment may be necessary for acne in the first few months of life, but the condition can leave scars in children as young as ages 3-6 months...
News
Beware a pair of dermatologic emergencies in children
- Author:
- Randy Dotinga
Patients with SSSS commonly have concurrent skin pain, fever, irritability, malaise, and poor feeding.
News
Prevention of HMA failure a goal for high-risk MDS posttransplant
- Author:
- Randy Dotinga
Not yet, hematologist/oncologist tells colleagues at Acute Leukemia Forum meeting.
News
Are HMAS appropriate for posttransplant maintenance in acute leukemias?
- Author:
- Randy Dotinga
Not yet, hematologist/oncologist tells colleagues at ALF meeting.
News
Novel agents hold promise for frontline AML treatment
- Author:
- Randy Dotinga
It’s time to move them beyond relapsed/refractory setting, leukemia specialist tells colleagues.
News
Novel treatments under study for chronic graft-versus-host disease in allo-HCT
- Author:
- Randy Dotinga
For now, though, options other than corticosteroids are limited, a hematologist-oncologist said.
News
Standard treatment lacking in relapsed refractory AML
- Author:
- Randy Dotinga
Clinical trials are still the best strategy, says a hematologist/oncologist.